CLINICAL USE, INSURANCE APPROVAL, AND LIPID LOWERING OF PCSK9 INHIBITORS IN A LARGE HEALTH SYSTEM

Samip Sheth, Niccole Cuccolo, Regina Vassalo,Natalie Blaine, Donald Wharton,Joseph Favatella,Erik Hossain,Jihane Hajj,Gayley Webb,Archna Bajaj,Daniel Soffer,Daniel Rader,Douglas Jacoby

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2020）

引用 0|浏览11

暂无评分

摘要

PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) were approved by the Food and Drug Administration in 2015. The approved indications included the treatment of clinical atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH) when additional lowering of low

查看译文

关键词

pcsk9 inhibitors,lipid,insurance approval

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要